Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Epigenetic regulation of macrophage polarization and inflammation by DNA methylation in obesity
Xianfeng Wang, Qiang Cao, Liqing Yu, Huidong Shi, Bingzhong Xue, Hang Shi
Xianfeng Wang, Qiang Cao, Liqing Yu, Huidong Shi, Bingzhong Xue, Hang Shi
View: Text | PDF
Research Article Inflammation

Epigenetic regulation of macrophage polarization and inflammation by DNA methylation in obesity

  • Text
  • PDF
Abstract

Obesity is associated with increased classically activated M1 adipose tissue macrophages (ATMs) and decreased alternatively activated M2 ATMs, both of which contribute to obesity-induced inflammation and insulin resistance. However, the underlying mechanism remains unclear. We find that inhibiting DNA methylation pharmacologically using 5-aza-2′-deoxycytidine or genetically by DNA methyltransferase 1 (DNMT1) deletion promotes alternative activation and suppresses inflammation in macrophages. Consistently, mice with myeloid DNMT1 deficiency exhibit enhanced macrophage alternative activation, suppressed macrophage inflammation, and are protected from obesity-induced inflammation and insulin resistance. The promoter and 5′-untranslated region of peroxisome proliferator-activated receptor γ1 (PPARγ1) are enriched with CpGs and are epigenetically regulated. The saturated fatty acids stearate and palmitate and the inflammatory cytokine TNF-α significantly increase, whereas the TH2 cytokine IL-4 significantly decreases PPARγ1 promoter DNA methylation. Accordingly, inhibiting PPARγ1 promoter DNA methylation pharmacologically using 5-aza-2′-deoxycytidine or genetically by DNMT1 deletion promotes macrophage alternative activation. Our data therefore establish DNA hypermethylation at the PPARγ1 promoter induced by obesity-related factors as a critical determinant of ATM proinflammatory activation and inflammation, which contributes to insulin resistance in obesity.

Authors

Xianfeng Wang, Qiang Cao, Liqing Yu, Huidong Shi, Bingzhong Xue, Hang Shi

×

Figure 8

PPARγ expression is regulated by DNA methylation.

Options: View larger image (or click on image) Download as PowerPoint
PPARγ expression is regulated by DNA methylation.
(A–F) PPARγ expression...
(A–F) PPARγ expression in 0.5 μM 5-aza-2′-deoxycytidine (5-azadC)–treated bone marrow–derived macrophages (BMDMs) (A) and RAW264.7 macrophages (B), in M1 (F4/80+CD11c+CD206–) and M2 (F4/80+CD11c–CD206+) adipose tissue macrophages (ATMs) (C), in BMDMs treated with 200 μM palmitate, 200 μM stearate, and 10 ng/ml TNF-α for 6 days (D), in ATMs isolated from low-fat-fed (LF-fed) and high-fat-fed (HF-fed) mice (E) and in ATMs isolated from saline- and 5-azadC–treated ob/ob and lean mice (F). (G) 5-Methyl cytidine levels and DNA methyltransferase 1 (DNMT1) binding at the PPARγ1 promoter in RAW264.7 macrophages treated with 10 ng/ml IL-4 and 0.5 μM 5-azadC for 4 days. (H) DNMT1 binding at the PPARγ1 promoter in BMDMs treated with 10 ng/ml IL-4, 0.5 μM 5-azadC, or 200 μM stearate (C:18) for 4 days. (I and J) PPARγ expression in BMDMs (I) and ATMs (J) isolated from myeloid-specific DNMT1 knockout (MD1KO) and fl/fl control mice. (K) PPARγ expression in RAW264.7 macrophages transfected with control (pLVX) or DNMT1-overexpressing plasmid and treated with IL-4 at the indicated doses for 4 days. Data are expressed as the mean ± SEM. n = 3–6. *P < 0.05. Groups labeled with different letters are statistically different from each other. Differences between groups were analyzed for statistical significance by Student’s t test or ANOVA with Fischer’s probable least-squares difference post hoc test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts